Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications

详细信息    查看全文

• 作者：Corinne Portioli ; Michele Bovi ; Donatella Benati ; Marta Donini ; Massimiliano Perduca ; Alessandro Romeo ; Stefano Dusi ; Hugo L. Monaco and Marina Bentivoglio
• 刊名：Journal of Biomedical Materials Research Part A
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：105
• 期：3
• 页码：847-858
• 全文大小：956K
• ISSN：1552-4965

文摘

For targeted brain delivery, nanoparticles (NPs) should bypass the blood-brain barrier (BBB). Novel functionalization strategies, based on low-density lipoprotein receptor (LDLR) binding domain, have been here tested to increase the brain targeting efficacy of poly d,l-lactic-co-glycolic acid (PLGA) NPs, biodegradable and suited for biomedical applications. Custom-made PLGA NPs were functionalized with an apolipoprotein E modified peptide (pep-apoE) responsible for LDLR binding, or with lipocalin-type prostaglandin-d-synthase (L-PGDS), highly expressed in the brain. At the comparison of pep-apoE and L-PGDS sequences, a highly homologs region was here identified, indicating that also L-PGDS could bind LDLR. Non-functionalized and functionalized NPs did not affect the viability of cultured human dendritic cells, protagonists of the immune response, and did not activate them to a proinflammatory profile. At 2 h after intravenous injection in mice, functionalized, but not the non-functionalized ones, fluorescent-tagged NPs were observed in the cerebral cortex parenchyma. The NPs were mostly internalized by neurons and microglia; glial cells showed a weak activation. The findings indicate that the tested functionalization strategies do not elicit adverse immune responses and that the peptidic moieties enable BBB traversal of the NPs, thus providing potential brain drug carriers. These could be especially effective for brain diseases in which LDLR is involved.